Colonic Propulsive Motility Model

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

This bead expulsion model is a method for evaluating a test compounds’ ability to alter colonic propulsive motility.

This model is designed to identify pharmacological agents that produce effects on propulsive motor activity and is an excellent predictor of drugs that may be useful for the therapy of irritable bowel syndrome (IBS) or constipation. This model can be modified to identify antagonists of constipative drugs or diarrhea producing drugs.

In this validation study, colonic propulsion was measured in mice treated with morphine, a well-described compound that reduces colonic motility.

This model is 1 of more than 60 models included in our theraTRACE® platform

Learn more

Ready to get started or looking for a custom model?

Contact us today for more information about our bespoke research models and to discuss how we can help you answer your unique research questions.

Discuss your project with us

Interested in running an Insulin Tolerance Test study?

If you are interested in learning more about the Insulin Tolerance Test (ITT), please contact us to start the conversation today!

Discuss your project with us
  • We chose Melior Discovery because they were responsive and cost effective.  We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail.  Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.

    Sridharan Rajamani, Ph.D., Senior Research Scientist

    Gilead Sciences
  • I have been working with Melior on a number of projects over the course of a few years now.  They have been a great partner throughout this time.  The scientists whom I have worked with have been great problem-solvers and were customer focused.

    Jay Lichter

    Avalon Ventures
  • Melior provided State-of-the-art Preclinical Pharmacology Support for a period of nearly a year where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.

    Richard DiMarchi, PhD

    Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences Indiana University, Department of Chemistry
  • Because Melior could do the orthotopic intracranial implants, we were able to do survival studies with brain tumor-bearing animals that were treated with our therapy, showing a beautiful survival with our agent versus control. Talk about something that gets your investors going! These beautiful survival curves with our agent versus control and visual photos are in all of our investor decks because… it's powerful.

    Bruce Ruggeri, Ph.D.

    Modifi Bio
  • Melior works in many therapeutic areas, like CNS, inflammatory disease, GI, cardiovascular, and oncology. I was very pleased that when it came to doing tumor studies, both subcutaneous and intracranial, they did them well. They reported on the studies on time and did the data analysis really well.

    Bruce Ruggeri, Ph.D.

    Modifi Bio
  • Their areas of expertise are extensive, and they are very experienced, responsive, and flexible in terms of how the study is run. Their pricing is reasonable, making them the best option for a young, not well-funded company like ours.

    Maxine Gowen

    Tamuro Bio
  • Melior’s team was very experienced and knowledgeable. They were always very open to suggestions and questions, spending a lot of time helping us feel comfortable with the study design. I would give them very high marks.

    Maxine Gowen

    Tamuro Bio
  • The most important factors in choosing to work with Melior were the fit between the tests they could run and our needs, as well as their tight budget and proximity. Melior was the best fit for our research goals.

    Ira Spector

    SFA Therapeutics

Graph showing higher latency in Morphine treated mice suggesting colonic propulsive motility

Latency to bead expulsion. CD1 mice (N=10) were injected with either vehicle or Morphine subcutaneously and thirty minutes later a 3mm glass bead is inserted into the distal colon of a mouse. Mice were monitored for up to thirty minutes and latency to bead expulsion was recorded. Morphine treated mice displayed a significantly higher latency to bead expulsion compared to vehicle treated animals. Data are mean ± SEM and evaluated using unpaired t-test; **p<0.01 compared to vehicle.

Morphine-treated animals can be used to screen antagonists of morphine-induced constipation, which is problematic in patients with extending treatment duration. This study validates the colonic expulsion assay and demonstrates that morphine, a well-described inhibitor of colonic propulsion, significantly attenuated propulsive activity.

This model is typically used to evaluate acute effects of test articles (after single administration). It exhibits relatively low variability typically yielding highly significant effects with groups sizes of 6 to 8 animals.

Related models

Influenza

Pulmonary Edema

LPS – Pulmonary Inflammation

Pulmonary Fibrosis

Respiratory Depression